Kintara Therapeutics(KTRA) - 2019 Q2 - Quarterly Report

PART I. - FINANCIAL INFORMATION Item 1. Financial Statements. The unaudited interim financial statements for the period ended December 31, 2018, detail the company's financial position, performance, and cash flows, highlighting a significant net loss and going concern uncertainty Consolidated Condensed Interim Balance Sheets Consolidated Condensed Interim Balance Sheets (Unaudited) | Item | December 31, 2018 ($) | June 30, 2018 ($) | | :-------------------------- | :-------------------- | :------------------ | | Cash and cash equivalents | 3,702,902 | 5,971,995 | | Total Assets | 4,037,552 | 7,074,855 | | Total Liabilities | 1,268,288 | 1,639,632 | | Total Stockholders' Equity | 2,769,264 | 5,435,223 | - The company's cash and cash equivalents decreased by approximately $2.27 million from June 30, 2018, to December 31, 2018[10] Consolidated Condensed Interim Statements of Loss and Comprehensive Loss Consolidated Condensed Interim Statements of Loss and Comprehensive Loss (Unaudited) | Item | Three months ended Dec 31, 2018 ($) | Three months ended Dec 31, 2017 ($) | Six months ended Dec 31, 2018 ($) | Six months ended Dec 31, 2017 ($) | | :------------------------------------------ | :---------------------------------- | :---------------------------------- | :-------------------------------- | :-------------------------------- | | Research and development | 947,249 | 2,141,945 | 1,966,369 | 4,076,588 | | General and administrative | 874,884 | 1,011,879 | 1,861,354 | 1,756,500 | | Net and comprehensive loss for the period | 1,809,697 | 3,161,598 | 3,801,501 | 5,828,004 | | Basic and fully diluted loss per share | 0.08 | 0.14 | 0.16 | 0.31 | - Net loss for the six months ended December 31, 2018, decreased by 34.79% to $3,801,501 from $5,828,004 in the prior year, primarily due to a significant reduction in research and development expenses[11] - Basic and fully diluted loss per share for the six months ended December 31, 2018, improved to $0.16 from $0.31 in the prior year[11] Consolidated Condensed Interim Statements of Cash Flows Consolidated Condensed Interim Statements of Cash Flows (Unaudited) | Cash Flow Activity | Six months ended Dec 31, 2018 ($) | Six months ended Dec 31, 2017 ($) | | :-------------------------------- | :-------------------------------- | :-------------------------------- | | Cash flows from operating activities | (3,049,876) | (4,505,604) | | Cash flows from financing activities | 780,783 | 8,941,158 | | (Decrease) increase in cash and cash equivalents | (2,269,093) | 4,435,554 | | Cash and cash equivalents - end of period | 3,702,902 | 11,021,568 | - Net cash used in operating activities decreased by 32.29% to $3,049,876 for the six months ended December 31, 2018, compared to $4,505,604 in the prior year[13] - Cash flows from financing activities significantly decreased by 91.29% to $780,783 for the six months ended December 31, 2018, from $8,941,158 in the prior year, primarily due to lower proceeds from share and warrant issuances[13] Notes to Consolidated Condensed Interim Financial Statements 1 Going concern, nature of operations, and corporate history Significant losses and negative cash flow raise substantial doubt about the company's ability to continue as a going concern, necessitating additional funding for its clinical trials - For the six months ended December 31, 2018, the Company reported a loss of $3,801,501 and negative cash flow from operations of $3,049,876[17] - As of December 31, 2018, the Company had an accumulated deficit of $56,299,291 and cash and cash equivalents of $3,702,902[17] - The Company is a clinical stage drug development company focused on cancer treatment, conducting clinical trials for VAL-083 as a potential treatment for glioblastoma multiforme[20] 2 Significant accounting policies The financial statements are prepared under U.S. GAAP, with key estimates involving derivative liability, equity instruments, and clinical trial accruals - The consolidated condensed interim financial statements are prepared in accordance with U.S. GAAP and presented in United States dollars, consolidating the Company and its wholly-owned subsidiaries[26][27] - Significant estimates are made for derivative liability, valuation of equity instruments issued for services, and clinical trial accruals[30] - The Company adopted ASU 2017-09 (Stock Compensation) and ASU 2016-01 (Financial Instruments) without material impact on its financial position or results of operations[33][35] - The Company is currently evaluating the potential impact of ASU 2017-11 (Financial Instruments with Down Round Features), ASU 2016-02 (Leases), and ASU 2018-07 (Nonemployee Shares-based Payment Accounting)[36][37][39] 3 Valent Technologies, LLC The company issued non-convertible Series A Preferred Stock to a related party, Valent Technologies, LLC, in exchange for a loan payable - The Company issued 278,530 shares of Series A Preferred Stock to Valent Technologies, LLC in exchange for a $278,530 loan payable[40] - Series A Preferred Stock has a stated value of $1.00 per share, is not convertible to common stock, and pays a 3% annual dividend[40] - Dividends of $2,089 and $4,178 were recorded for the three and six months ended December 31, 2018, respectively, as a direct increase in accumulated deficit[41] 4 Derivative liability Certain common stock purchase warrants are classified as a derivative liability and re-measured at fair value each period, resulting in a significant decrease in liability - Certain common stock purchase warrants are classified as a derivative liability, recognized and re-measured at fair value each reporting period[42] Derivative Liability Summary | Item | December 31, 2018 ($) | December 31, 2017 ($) | | :-------------------------- | :-------------------- | :-------------------- | | Opening balance (Six months) | 1,117 | 61,228 | | Change in fair value of warrants (Six months) | (1,041) | (55,679) | | Closing balance (Six months) | 76 | 5,549 | | Closing balance (Three months) | 76 | 5,549 | - The derivative liability decreased from $1,117 at June 30, 2018, to $76 at December 31, 2018, consisting of 21,768 2015 Agent Warrants[44] 5 Stockholders' equity This section details changes in stockholders' equity, including preferred and common stock issuances, conversions, and equity-based compensation plans Series B Preferred Shares - Series B Preferred Stock is convertible into 2.5 shares of common stock at $3.20 per share and pays a 9% annual cumulative dividend in common stock[45] - During the three and six months ended December 31, 2018, the Company issued 47,352 and 96,954 common shares, respectively, as Series B Preferred Stock dividends, recognizing $16,190 and $52,275 as an increase in accumulated deficit[48] - 40,000 Series B Preferred shares were converted to 100,000 common shares during the three and six months ended December 31, 2018. As of December 31, 2018, 841,113 Series B shares remain outstanding, convertible into 2,102,792 common shares[49] Series A Preferred Shares - 278,530 shares of Series A Preferred Stock are designated with a stated value of $1.00 per share, are not convertible into common stock, and entitle the holder to a 3% annual dividend[50] - In liquidation, Series A holders are entitled to their stated value plus accrued unpaid dividends prior to common stockholders[50] Common stock Changes in Common Stock and Equity Accounts (Six Months Ended Dec 31, 2018) | Item | Shares of common stock outstanding | Common stock ($) | Additional paid-in capital ($) | Warrants ($) | Accumulated deficit ($) | | :--------------------------------------- | :------------------------------- | :--------------- | :----------------------------- | :----------- | :---------------------- | | Balance – June 30, 2018 | 22,966,668 | 22,967 | 43,177,523 | 8,229,482 | (52,441,337) | | Exercise and exchange of warrants | 2,966,666 | 2,967 | 2,934,211 | (2,210,697) | - | | Warrants issued for services | - | - | - | 27,802 | - | | Conversion of Series B preferred stock | 100,000 | 100 | 278,951 | - | - | | Series B Preferred stock dividend | 96,954 | 96 | 52,179 | - | (52,275) | | Shares issued for services | 13,131 | 13 | 6,743 | - | - | | Stock option expense | - | - | 255,653 | - | - | | Performance stock unit expense | - | - | 123,028 | - | - | | Series A Preferred cash dividend | - | - | - | - | (4,178) | | Loss for the period | - | - | - | - | (3,801,501) | | Balance – December 31, 2018 | 26,143,419 | 26,143 | 46,828,288 | 6,046,587 | (56,299,291) | - As of December 31, 2018, 26,143,419 common shares were issued and outstanding, an increase from 22,966,668 at June 30, 2018[51] - In the six months ended December 31, 2017, the Company completed a registered direct offering of 8,000,000 common shares and warrants for $10.0 million gross proceeds, incurring $800,000 in cash commission and issuing warrants for 400,000 shares to the placement agent[52][53][54] 2017 Omnibus Incentive Plan - The 2017 Omnibus Equity Incentive Plan reserves 7,800,000 shares of common stock for issuance, less shares issued under the Legacy Plan[55] - As of December 31, 2018, 1,699,850 shares were issued/subject to options under the Legacy Plan, 1,226,979 under the 2017 Plan, and 1,200,000 PSUs were issued under the 2017 Plan[55] Performance stock units - 1,200,000 Performance Stock Units (PSUs) were outstanding as of December 31, 2018, granted to directors under the 2017 Plan[56] - PSUs vest upon achieving specific fully diluted market capitalization levels, with full vesting occurring upon the later of one year from grant date and achieving a $500 million market capitalization for five consecutive business days[56] - The Company recognized $123,028 in expense related to PSUs for the six months ended December 31, 2018, with $403,113 in unrecognized compensation expense remaining[57] Stock Options Stock Options Activity | Item | Number of stock options | Weighted average exercise price ($) | | :-------------------------- | :---------------------- | :-------------------------------- | | Balance – June 30, 2018 | 2,626,829 | 2.43 | | Granted | 300,000 | 0.61 | | Balance – December 31, 2018 | 2,926,829 | 2.24 | - As of December 31, 2018, 2,926,829 stock options were outstanding, with 1,691,706 exercisable[61] - The Company recognized $255,653 in stock option expense for the six months ended December 31, 2018, with $332,988 in unrecognized compensation expense remaining[62] Warrants Changes in Outstanding Warrants (Six Months Ended Dec 31, 2018) | Description | Number | | :-------------------------- | :------- | | Balance – June 30, 2018 | 14,281,275 | | Exercised for cash | (1,975,000) | | Cashless exchange | (2,975,000) | | Issued for services | 140,000 | | Forfeited | (24,000) | | Expired | (43,750) | | Balance - December 31, 2018 | 9,403,525 | - The Company received net proceeds of $726,481 from the exercise of 1,975,000 2018 Investor Warrants at a reduced exercise price of $0.40 per share[64] - An aggregate of 991,666 common shares were issued in exchange for 2,975,000 2018 Investor Warrants, reducing fully-diluted common shares by 1,983,334[65] 6 Financial instruments The company's financial instruments' carrying values approximate fair value, with the derivative liability measured using a Level 3 Black-Scholes model - The Company's financial instruments include cash and cash equivalents, other receivables, accounts payable, related party payables, and derivative liability[72] - The carrying values of cash, receivables, and payables approximate their fair values due to immediate or short-term maturity[72] - The derivative liability, consisting of certain warrants, is fair valued at each reporting period using a Black-Scholes Option Pricing Model and is classified as a Level 3 financial instrument due to unobservable inputs like volatility[73][74] 7 Supplementary statement of cash flows information This section details non-cash financing activities, including stock dividends, share conversions, and accrued issuance costs Supplementary Cash Flow Information (Six Months Ended Dec 31) | Item | 2018 ($) | 2017 ($) | | :------------------------------------------ | :------- | :------- | | Series B Preferred share common stock dividend | 52,275 | 95,732 | | Series B Preferred shares converted to common stock | 279,051 | - | | Share issuance costs accrued | 58,480 | - | 8 Subsequent events The company issued a small number of common shares for services after the reporting period ended - Subsequent to December 31, 2018, the Company issued 4,874 shares of common stock for services[78] Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations. Management discusses the company's financial condition, operational results, clinical study progress for VAL-083, and significant liquidity challenges raising going concern doubts Recent Highlights - The Nasdaq Capital Market LLC granted the Company an extension until June 25, 2019, to regain compliance with the Minimum Bid Price requirement[83] - As of January 31, 2019, 46 of 48 planned patients were enrolled in the Phase 2 study of VAL-083 in bevacizumab-naïve, recurrent glioblastoma multiforme (rGBM) patients with MGMT-unmethylated status at MD Anderson Cancer Center[83] - As of January 31, 2019, 14 of up to 30 planned patients were enrolled in the Phase 2 study of VAL-083 in newly-diagnosed, MGMT-unmethylated GBM patients in Guangzhou, China[83] VAL-083 Clinical Studies Focus on MGMT-unmethylated GBM - The company is focusing VAL-083 development on MGMT-unmethylated GBM patients, who comprise approximately two-thirds of GBM cases and are resistant to standard-of-care temozolomide (TMZ)[85][86] - VAL-083's anti-tumor mechanism is active independent of MGMT status, suggesting its potential as a replacement for TMZ in MGMT-unmethylated GBM[87] Phase 2 Study in MGMT-unmethylated rGBM in Collaboration with University of Texas MD Anderson Cancer Center - The Phase 2 study at MDACC, initiated in February 2017, enrolls up to 48 MGMT-unmethylated rGBM patients not previously treated with Avastin, with overall survival as the primary endpoint[89] - As of January 31, 2019, 46 patients were enrolled. The protocol was amended to reduce the starting dose of VAL-083 to 30mg/m² (from 40mg/m²) and modify patient screening platelet count to improve tolerance and maximize exposure in heavily pre-treated patients[90] - Full enrollment is forecasted for Q1 2019, with data to inform future clinical study designs[92] Phase 2 Study in Newly Diagnosed MGMT-unmethylated GBM - A single-arm Phase 2 study in newly diagnosed MGMT-unmethylated GBM patients was initiated in September 2017 at Sun Yat-sen University Cancer Center in China, combining VAL-083 with radiotherapy[94][95] - The study aims to enroll up to 30 patients, with efficacy endpoints including tumor response, PFS, PFS6, and OS. The dose-confirmation phase selected 30 mg/m² for combination with irradiation[96][97] - As of January 31, 2019, 14 patients were enrolled. Data will be used to establish a dosing regimen and study design for advanced registration-directed clinical studies[97][98] Ovarian Cancer - VAL-083 received FDA orphan drug designation for ovarian cancer in April 2016[99] - An IND for a Phase 1/2 study in recurrent platinum-resistant ovarian cancer was filed in September 2017, but the company is reassessing the program and evaluating strategic options, including combination with PARP inhibitors[99][100] Fast Track Designation - VAL-083 received FDA Fast Track designation for rGBM in December 2017, which expedites review for life-threatening diseases with unmet medical needs[101][102] - Benefits include increased communication with the FDA, potential for Accelerated Approval, Priority Review, and Rolling Review, aiming for earlier drug approval[102] Current Treatments for Gliomas and Glioblastoma Multiforme - GBM is the most common and lethal form of glioma, with a poor prognosis; median overall survival for newly diagnosed patients is less than 15 months, and 12.2 months for unmethylated GBM[104] - Standard treatment involves surgical resection, followed by radiotherapy with concomitant and adjuvant temozolomide, with or without tumor treating fields. MGMT-unmethylated GBM patients may receive radiation alone due to TMZ resistance[105] VAL-083 Mechanism of Action and the Opportunity in the Treatment of Cancer - VAL-083 is a novel DNA-targeting agent with a unique mechanism of action, forming inter-strand crosslinks at the N position of guanine on DNA, leading to cell-cycle arrest and lethal double-strand DNA breaks[107][109] - VAL-083 has demonstrated activity in cell lines resistant to other chemotherapies, including MGMT-unmethylated GBM, p53 mutated NSCLC, ovarian cancer, and medulloblastoma[108][110] - The main dose-limiting toxicity is myelosuppression, particularly thrombocytopenia, which is manageable with modern medicine, and there is no evidence of lung, liver, or kidney toxicity[112][113] Corporate History - DelMar Pharmaceuticals, Inc. was formed on June 24, 2009, as Berry Only, Inc., and became the parent company of Del Mar Pharmaceuticals (BC) Ltd. through a reverse acquisition on January 25, 2013[114] Outstanding Securities Outstanding Securities as of February 11, 2019 | Security Type | Quantity | | :-------------------------------- | :--------- | | Common stock issued and outstanding | 25,585,533 | | Common stock issuable upon exchange of Exchangeable Shares | 562,761 | | Warrants to purchase common stock | 9,403,525 | | Series B Preferred Stock outstanding | 841,113 | | Common stock issuable from Series B conversion | 2,102,792 | | Stock options to purchase common stock | 2,926,829 | | Performance Stock Units (PSUs) | 1,200,000 | Related Parties - Valent Technologies, LLC, owned by Dr. Dennis Brown (Chief Scientific Officer), is a related party due to the acquisition of initial patents and technology rights[117] Selected Quarterly Information Selected Balance Sheet Data Selected Balance Sheet Data | Item | December 31, 2018 ($) | June 30, 2018 ($) | | :-------------------------- | :-------------------- | :------------------ | | Cash and cash equivalents | 3,702,902 | 5,971,995 | | Working capital | 2,751,675 | 5,407,929 | | Total assets | 4,037,552 | 7,074,855 | | Total stockholders' equity | 2,769,264 | 5,435,223 | Selected Statement of operations data (Three Months Ended) Selected Statement of Operations Data (Three Months Ended Dec 31) | Item | 2018 ($) | 2017 ($) | | :------------------------------------------ | :------- | :------- | | Research and development | 947,249 | 2,141,945 | | General and administrative | 874,884 | 1,011,879 | | Net and comprehensive loss for the period | 1,809,697 | 3,161,598 | | Basic loss per share | 0.08 | 0.14 | Selected Statement of operations data (Six Months Ended) Selected Statement of Operations Data (Six Months Ended Dec 31) | Item | 2018 ($) | 2017 ($) | | :------------------------------------------ | :------- | :------- | | Research and development | 1,966,369 | 4,076,588 | | General and administrative | 1,861,354 | 1,756,500 | | Net and comprehensive loss for the period | 3,801,501 | 5,828,004 | | Basic loss per share | 0.16 | 0.31 | Expenses net of non-cash, share-based compensation expense Expenses Net of Non-Cash, Share-Based Compensation (Three Months Ended Dec 31) | Item | 2018 ($) | 2017 ($) | | :---------------------------------------------------- | :------- | :------- | | Research and development net of non-cash compensation | 921,505 | 2,015,570 | | General and administrative net of non-cash compensation | 716,605 | 909,747 | Expenses Net of Non-Cash, Share-Based Compensation (Six Months Ended Dec 31) | Item | 2018 ($) | 2017 ($) | | :---------------------------------------------------- | :------- | :------- | | Research and development net of non-cash compensation | 1,908,035 | 3,955,187 | | General and administrative net of non-cash compensation | 1,506,449 | 1,586,005 | Results of Operations Comparison of the three months ended December 31, 2018 and December 31, 2017 Key Financial Changes (Three Months Ended Dec 31, 2018 vs. 2017) | Item | 2018 ($) | 2017 ($) | Change ($) | Change (%) | | :---------------------------------- | :------- | :------- | :--------- | :--------- | | Research and development | 947,249 | 2,141,945 | (1,194,696) | (56) | | General and administrative | 874,884 | 1,011,879 | (136,995) | (14) | | Net loss and comprehensive loss | 1,809,697 | 3,161,598 | (1,351,901) | (43) | - Research and development expenses decreased by 56% due to lower clinical development costs (parking of STAR-3 study), personnel costs (settlement agreement in prior year), preclinical research, and non-cash, share-based compensation[127][128][129] - General and administrative expenses decreased by 14% primarily due to lower professional fees and personnel costs, partially offset by higher non-cash, share-based compensation (PSUs issued in April 2018)[130][131] - The company recognized a gain of $1,261 from the change in fair value of derivative liability in Q4 2018, compared to a loss of $889 in Q4 2017, driven by changes in common stock price[133][134] Comparison of the six months ended December 31, 2018 and December 31, 2017 Key Financial Changes (Six Months Ended Dec 31, 2018 vs. 2017) | Item | 2018 ($) | 2017 ($) | Change ($) | Change (%) | | :---------------------------------- | :------- | :------- | :--------- | :--------- | | Research and development | 1,966,369 | 4,076,588 | (2,110,219) | (52) | | General and administrative | 1,861,354 | 1,756,500 | 104,854 | 6 | | Net loss and comprehensive loss | 3,801,501 | 5,828,004 | (2,026,503) | (35) | - Research and development expenses decreased by 52% due to the parking of the STAR-3 Phase 3 study, lower personnel costs, reduced preclinical research, and decreased intellectual property and travel costs[140][141][142] - General and administrative expenses increased by 6% primarily due to higher non-cash, share-based compensation (PSUs issued in April 2018), partially offset by decreased professional fees and travel costs[143][144] - The company recognized a gain of $1,041 from the change in fair value of derivative liability for the six months ended December 31, 2018, compared to a gain of $55,679 in the prior year[145][146] Liquidity and Capital Resources Operating Activities - Net cash used in operating activities decreased to $3,049,876 for the six months ended December 31, 2018, from $4,505,604 in the prior year, despite reporting net losses of $3,801,501 and $5,828,004, respectively[150] - Significant changes in non-cash working capital included a $420,679 decrease in cash from reduced accounts payable and accrued liabilities, and a $728,276 increase in cash from decreased prepaid expenses and deposits (due to a partial refund for the STAR-3 study)[151] Financing Activities - For the six months ended December 31, 2018, the company received $784,961 in net proceeds from warrant exercises[152] - In the prior year (six months ended December 31, 2017), the company received $8,945,336 in net proceeds from a registered direct offering of common stock and warrants[152] Going Concern and Capital Expenditure Requirements - The company's accumulated deficit of $56,299,291 and negative operating cash flow of $3,049,876 for the six months ended December 31, 2018, along with no revenues, raise substantial doubt about its ability to continue as a going concern[154] - Management is pursuing new equity issuance and/or strategic partnership arrangements to secure necessary financing, but there is no assurance of success[155] - Future funding requirements depend on clinical trial progress, manufacturing costs, intellectual property protection, and potential acquisitions. Failure to secure funding may lead to delays, reduced scope of programs, or earlier partnering[157][158] Critical Accounting Policies - Critical accounting policies include warrants and shares issued for services, stock options, performance stock units, derivative liability, and clinical trial accruals[163] - Stock-based awards (stock options, PSUs) are measured at fair value using models like Black-Scholes or Monte Carlo simulation, with compensation expense recognized over the service period[164][165] - Derivative liability (warrants) is fair valued at each reporting period using a binomial or Black-Scholes model, with changes recorded in the statement of loss[166] - Clinical trial expenses are accrued based on estimates of work performed, patient enrollment, services provided, and contractual terms[167] Off-Balance Sheet Arrangements - The Company does not have any off-balance sheet arrangements[168] Item 3. Quantitative and Qualitative Disclosures About Market Risk. The company is exempt from providing quantitative and qualitative disclosures about market risk as a smaller reporting company - Quantitative and Qualitative Disclosures About Market Risk are not required for a smaller reporting company[169] Item 4. Controls and Procedures. Management concluded that disclosure controls and procedures were ineffective as of December 31, 2018, due to a material weakness in internal control over financial reporting - Management concluded that disclosure controls and procedures were not effective as of December 31, 2018, due to a material weakness in internal control over financial reporting[170] - No material changes in internal control over financial reporting occurred during the quarter ended December 31, 2018[171] PART II - OTHER INFORMATION Item 1. Legal Proceedings. The company is not currently involved in any legal proceedings - There are no legal proceedings the Company is party to or any of its property is subject to[174] Item 1A. Risk Factors. The company's primary updated risk factor is the potential delisting from Nasdaq for failing to meet the minimum bid price requirement - No material changes to risk factors previously disclosed in the Annual Report on Form 10-K, except for the Nasdaq listing compliance[176] - The company received an extension until June 25, 2019, to regain compliance with Nasdaq's $1.00 minimum bid price requirement[179] - Failure to regain compliance could lead to delisting, reducing common stock liquidity and price, harming capital-raising ability, and potentially impacting investor confidence[180] Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. The company issued common shares, options, and warrants for services and dividends under a registration exemption from the Securities Act of 1933 - During the three months ended December 31, 2018, the Company issued 47,352 common shares as Series B Preferred Stock dividends and 6,068 common shares for services[182] - Options to purchase 300,000 common shares and warrants to purchase 20,000 common shares were granted for services[182] - These issuances relied on the exemption from registration provided by Section 4(a)(2) under the Securities Act of 1933[183] Item 3. Defaults Upon Senior Securities. There were no defaults upon senior securities during the reporting period - There were no defaults upon senior securities[184] Item 4. Mine Safety Disclosures. This item is not applicable to the company - Mine Safety Disclosures are not applicable[185] Item 5. Other Information. There is no other information to report under this item - No other information to report[186] Item 6. Exhibits. This section lists the exhibits filed with the Form 10-Q, including officer certifications and XBRL data files List of Exhibits | No. | Description | | :---------- | :--------------------------------------------------- | | 31.1 | Rule 13a-14(a)/ 15d-14(a) Certification of Chief Executive Officer* | | 31.2 | Rule 13a-14(a)/ 15d-14(a) Certification of Chief Financial Officer* | | 32.1 | Section 1350 Certification of Chief Executive Officer** | | 32.2 | Section 1350 Certification of Chief Financial Officer** | | EX-101.INS | XBRL INSTANCE DOCUMENT | | EX-101.SCH | XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT | | EX-101.CAL | XBRL TAXONOMY EXTENSION CALCULATION LINKBASE | | EX-101.LAB | XBRL TAXONOMY EXTENSION LABELS LINKBASE | | EX-101.PRE | XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE |